BUSINESS

• Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
  March 10, 2025

• Astellas, Yaskawa Electric to Form JV for Cell Therapy Production
  March 10, 2025

• Sandoz’s Rituxan Biosimilar Adds Nephrotic Syndrome Use
  March 10, 2025

• Japan Ethical Drug Sales Up 3.8% in January: Crecon
  March 10, 2025

• Novartis Adjusts Entresto Shipments Ahead of Price Hike in Off-Year Revision
  March 7, 2025

• Off-Year Revision Is Problematic, Leads to Hesitation in Investment: Novo CEO
  March 7, 2025

• Keytruda Tops Japan Drug Ranking for 17th Months on End: Encise
  March 7, 2025

• Maruishi Files Midazolam Oral Syrup for Pediatric Use
  March 7, 2025

• J&J Files Tremfya SC Induction Regimen for UC in Japan
  March 7, 2025

• Novo Bolsters Wegovy Label in Japan with CV Outcome Data
  March 6, 2025

• AZ Wins Certification to Allow Use of Pseudonymized Medical Info
  March 6, 2025

• DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
  March 6, 2025

• Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response
  March 5, 2025

• Meiji Invests in French Vaccine Player Osivax
  March 5, 2025

• Sumitomo Group Continues to Seek Best Partners for Pharma Biz
  March 5, 2025

• Protagonist/Takeda’s Hematology Med Makes Mark in PIII
  March 5, 2025

• Sato, Eisai to Wind Up Collab on Antifungal Nailin
  March 5, 2025

• Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
  March 5, 2025

• Enhertu Hits OS Goal in 2nd-Line Gastric Cancer Use
  March 5, 2025

• Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
  March 5, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 60
• 61
• 62
• 63
• 64
• 65
• 66
• 67
• 68
• …
• Next ›
• 最終 »